Compare ARLP & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | BEAM |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1999 | 2019 |
| Metric | ARLP | BEAM |
|---|---|---|
| Price | $25.22 | $25.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $32.33 | ★ $49.85 |
| AVG Volume (30 Days) | 311.8K | ★ 1.8M |
| Earning Date | 10-26-2026 | 11-03-2026 |
| Dividend Yield | ★ 9.57% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,002,857,000.00 | $24,000.00 |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | $3.94 | N/A |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | 11.50 | ★ 33.33 |
| 52 Week Low | $23.01 | $20.23 |
| 52 Week High | $29.45 | $38.26 |
| Indicator | ARLP | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 49.69 |
| Support Level | $23.96 | $22.98 |
| Resistance Level | $25.33 | $27.30 |
| Average True Range (ATR) | 0.59 | 1.84 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 38.10 | 38.50 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties, and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland, and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex, and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II, and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties have included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.